Barclays PLC Acquires 12,979 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Barclays PLC grew its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 54.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,602 shares of the biopharmaceutical company’s stock after purchasing an additional 12,979 shares during the period. Barclays PLC owned approximately 0.06% of Theravance Biopharma worth $397,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of TBPH. Principal Financial Group Inc. bought a new stake in shares of Theravance Biopharma in the first quarter valued at approximately $101,000. Acadian Asset Management LLC raised its position in shares of Theravance Biopharma by 51.6% in the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,818 shares during the period. Vanguard Group Inc. increased its holdings in Theravance Biopharma by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after acquiring an additional 648,124 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Theravance Biopharma by 3.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 402,640 shares of the biopharmaceutical company’s stock worth $3,850,000 after acquiring an additional 12,095 shares during the period. Finally, UBS Group AG increased its holdings in Theravance Biopharma by 45.0% during the 1st quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 1,101 shares during the period. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

TBPH stock opened at $9.75 on Wednesday. Theravance Biopharma, Inc. has a one year low of $8.89 and a one year high of $12.03. The stock has a market cap of $514.90 million, a PE ratio of 0.86 and a beta of 0.45. The firm has a 50 day simple moving average of $9.93 and a two-hundred day simple moving average of $10.52.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Theravance Biopharma had a negative return on equity of 16.88% and a net margin of 1,694.17%. The company had revenue of $13.75 million during the quarter, compared to analysts’ expectations of $15.24 million. On average, research analysts expect that Theravance Biopharma, Inc. will post -1.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Theravance Biopharma in a report on Tuesday, August 8th. StockNews.com assumed coverage on shares of Theravance Biopharma in a report on Thursday, August 17th. They set a “hold” rating on the stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.